Histone deacetylases in cardiac fibrosis: Current perspectives for therapy

详细信息    查看全文

• 作者：Hui Tao ; Kai-Hu Shi ; Jing-Jing Yang ; Cheng Huang ; Hong-Ying Zhan ; Jun Li
• 关键词：HDACs ; Histone deacetylases ; ECM ; Extracellular matrix ; 伪-SMA ; 伪-smooth muscle actin ; HATs ; Histone acetyltransferases ; TGF-尾1 ; Transforming growth factor 尾1 ; PDGF ; Platelet-derived growth factor ; FGF ; Fibroblast growth factor ; TIMPs ; Tissue inhibitors of matrix metalloproteinases ; MEF2 ; Myocyte enhancer factor-2 ; IGF-IIR/Man-6-P ; IGF-II/mannose 6-phosphate receptor ; NRVMs ; Neonatal rat ventricular myocytes ; PKD1 ; Protein kinase D1
• 刊名：Cellular Signalling
• 出版年：March, 2014
• 年：2014
• 卷：26
• 期：3
• 页码：521-527
• 全文大小：484 K

文摘

Cardiac fibrosis is an important pathological feature of cardiac remodeling in heart diseases. The molecular mechanisms of cardiac fibrosis are unknown. Histone deacetylases (HDACs) are enzymes that balance the acetylation activities of histone acetyltransferases on chromatin remodeling and play essential roles in regulating gene transcription. In recent years, the role of HDACs in cardiac fibrosis initiation and progression, as well as the therapeutic effects of HDAC inhibitors, has been well studied. Moreover, numerous studies indicated that HDAC activity is associated with the development and progression of cardiac fibrosis. In this review, the innovative aspects of HDACs are discussed, with respect to biogenesis, their role in cardiac fibrosis. Furthermore, the potential applications of HDAC inhibitors in the treatment of cardiac fibrosis associated with fibroblast activation and proliferation.